Joseph Taleb
@Joseph_Taleb
Followers
272
Following
1K
Media
11
Statuses
190
Excited to have our SHOCK TEAM paper published in @CircAHA, thanks to the extraordinary multidisciplinary team @UofUHealth, #AHAFunded & #NIHFunded. Eagerly anticipating more contributions to the field! @taraloujones @aloboMD @nataliemwall @jadzdanaf @MikeYin19 @StavrosDrakos
The multidisciplinary Shock Team approach for the treatment of refractory cardiogenic shock decreased in-hospital and 30-day all-cause mortality https://t.co/rEIynqx2sN | #AHAJournals @JoeTonnaMD @StavrosDrakos @Joseph_Taleb @UofUHealth
2
5
26
Post fellowship recruitment happy hour (on the beach)! Life is good as a @UCSDCardiology fellow. Come join us!
1
3
17
Congratulations @Lpa_Doc on receiving the Family Heart Foundation Pioneer Award! I cannot think of anyone more deserving! @FamilyHeartFdn @UCSDCardiology @UCSDCardFellows
0
3
32
Honored to contribute as a panelist in the #SCAI Shock Think Tank on the Economics of Shock. Thought-provoking discussions, great insights, and important gaps identified. Grateful to @JasonKatzMD @BalimSenmanMD @SocietyOfCCC @StavrosDrakos @UCSDCardFellows
Kicking off the @SocietyOfCCC and @SCAI Cardiogenic Shock Team Think Tank w/ diverse perspectives from diverse stakeholders!
1
1
11
Proud to share our review on transthyretin amyloid cardiomyopathy! https://t.co/giACwEptSR We break down the current treatments, what’s in the pipeline, and what’s next. @UreyTony @UCSDCardiology
link.springer.com
Cardiology and Therapy - Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease caused by the deposition of insoluble amyloid fibrils derived from misfolded transthyretin (TTR)....
0
15
24
PROs provide valuable insight into pts health status, but can they be used to improve risk prediction in HF? 💡In this study, adding PROs to risk models improved ability to predict adverse events. How does your HF program utilize PRO assessments? 🔗 https://t.co/s2sFt5tHhy
0
7
14
At last—our analysis predicting severe outcomes in ICI-myocarditis is out. With just ECG, LVEF, troponin, and clinical history, you can estimate risk at initial presentation. Grateful for the incredible mentorship @CardioOncology @DrJESalem .. true world-class investigators!
Excited to report this important collaboration which we hope helps us understand ICI-myocarditis better, published in #EHJ today! Along with the great @DrJESalem! @ehj_ed @JBauersachsMD #CardioOnc @UCSFCardiology @UCSFCancer
https://t.co/3jsZaZ2SuQ
0
3
29
Left Atrial Reverse Remodeling in Patients Supported with Durable Left Ventricular Assist Devices and Clinical Implications @JosefStehlik @TomHanffMD @Joseph_Taleb @CPKyriakopoulos @StavrosDrakos @UofUHealth @UofUCV @UofUInternalMed @NEH_CVRTI #AHAJournals
https://t.co/Kcaur6ezQe
0
10
22
Honored to participate and present our work at another @ISHLT meeting and grateful to our amazing team of clinicians and researchers @UofUCV & @NEH_CVRTI for the support and mentorship !! Already looking forward to #ISHLT2026 !! @StavrosDrakos @JosefStehlik @UofUInternalMed
1
5
17
Thrilled to share our work on the cost-effectiveness of MCS in refractory cardiogenic shock #ISHLT2025. Grateful to my mentors & collaborators! Energized by the science and inspired by the people @StavrosDrakos @CPKyriakopoulos @tgiannouchos @TomHanffMD @UCSDCardFellows
1
7
23
Congrats @CPKyriakopoulos and team! In this cohort of CS patients transferred from spoke to hub 🏥, we identified 🔑 factors, both inherent and management-related, linked to better outcomes. Insights to help guide escalation of care! @UCSDCardFellows @UCSDCardiology
Excited to share our publication @JAHA_AHA studying spoke-to-hub #CS transfers ! Shorter stay & transfer from ⬇️ level of care spoke, ⬇️ VIS at admission to the hub & shorter time to tMCS assoc w/ ⬆️ rates of NHS @UofUHealth @UofUCV @UofUInternalMed
https://t.co/CezhUT0i9n
0
2
3
Want to attend #UCARS25 to enjoy the terrific bench-to-bedside agenda but can’t make the trip to scenic SLC, Utah? Join live with our Complimentary Live Feed Broadcast - Register Now: https://t.co/DiqgPa1htr Agenda, Feb 20 & 21, 2025: https://t.co/1EI54bg86x
medicine.utah.edu
1/ #UCARS25 Abstract Deadline Jan 12 : https://t.co/SW8SpV5MMl Terrific Agenda: opportunity to interact with leading experts: @HowardARockman @KiranKhush1 @RobGersztenMD @PilarAlcaidePhD @SmarxLab @JasonKatzMD @LiviuKlein @NirUrielMD @Netuka_ivan @manreetkanwar @stevenhsu_md
0
19
33
From a fellowship conversation @UTSWCardfellow with @MarkDrazner to publication with @UofUInternalMed data. Excellent review by @kon_sideris of hemodynamic parameters in hf/cardiogenic shock and presentation of the very high risk “Sideris sign” 😄
RHC remains key in advanced HF/CS care, with markers like CPO, API, PAPi, RAP/PCWP, and RVSWI refining risk stratification. Novel finding: RAP > PA sat = 71% 30-day mortality. Better hemodynamics = better outcomes ( https://t.co/ec3i8bfwKh).
#HREV @SotiriaLiori @JamesCFangMD
1
8
26
Breaking news for the lipid community: the FDA has approved Ionis’ medicine – the first and only treatment for adults with FCS in the U.S. as an adjunct to diet. Proud to be part of a determined, dedicated team. Read more: https://t.co/pXIK54siw6
8
24
100
1/ #UCARS25 Agenda: https://t.co/1EI54bg86x Submit abstract by Jan 5! Interact with leading experts/guest faculty: @HowardARockman @KiranKhush1 @RobGersztenMD @PilarAlcaidePhD @SmarxLab
@JasonKatzMD @LiviuKlein @NirUrielMD @Netuka_ivan @manreetkanwar @stevenhsu_md
2
30
51
Patients with LVAD demonstrate substantial cardiomyocyte regeneration, highlighting a potential therapeutic avenue @frisenjonas @Joseph_Taleb @SJovinge @ThirupuraShank1 @CPKyriakopoulos @mandra @oibergmann
https://t.co/U2RQhzLSTo
1
24
30
Thank you all for the collaborative research leading to an important discovery! One more big step towards understanding the mechanisms driving reverse remodeling and #MyocardialRecovery @NEH_CVRTI @RobinShawCVRTI @RutterLab @molecularpepsi @ScottSummers339 @ChaudhuriLab
Excited to share the latest collaboration spearheaded by @oibergmann @FrisenJonas @StavrosDrakos this work started with our Leducq consortium 6 years ago showing that LVAD responders have a higher rate of new myocytes formation.
0
11
28
Thrilled to share our study in Circulation! https://t.co/hmUIrjgnGG Led by @oibergmann, we found a >6-fold boost in cardiac regeneration in LVAD responders vs healthy hearts. Honored to be part of this transformative research. @UofUCV @UCSDCardiology
ahajournals.org
BACKGROUND: Cardiomyocytes in the adult human heart show a regenerative capacity, with an annual renewal rate of ≈0.5%. Whether this regenerative capacity of human cardiomyocytes is employed in heart...
0
3
10
Important insights paving the way forward! This group of younger patients also has a high probability of VAD-mediated myocardial recovery which is an outcome that can improve their long-term prognosis even more: https://t.co/qpPSAB61lf
pubmed.ncbi.nlm.nih.gov
The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update
0
8
25
The Shock Team approach for treating refractory CS may be a cost-effective alternative to traditional SoC. These findings can help prioritize the implementation of Shock Team initiatives to further improve cardiogenic shock outcomes.
0
0
0
PSA estimates showed that the Shock Team was cost-effective in the majority of simulations using a willingness-to-pay threshold of $150,000, while it was also dominant in almost one-third of the simulations
1
0
2